Providing a Better Decision Making Process for Pharmaceutical and Life Sciences Leaders
Helping Pharmaceutical Companies Reduce Risk in Decision Making
The urgency to replace the revenue of blockbuster drugs - going off patent - makes for challenging times in the pharmaceutical industry. Manufacturers are faced with high risk decisions on choosing which compounds and indications to pursue, planning clinical trials to yield the most conclusive evidence on safety and efficacy, selecting the right contract research organization to conduct trials and redefining entire corporate strategies to navigate the new competitive landscape.
Decisions on these matters are much too complex for any one person to make. So companies entrust that responsibility to committees and groups of subject matter experts. But the problem is, group decision making is hard.
Decision Lens offers a decision support solution that helps pharmaceutical companies significantly reduce the risk in making complex decisions they face today. Leveraging a scientifically proven methodology developed at the Wharton School of Business, Decision Lens replaces unstructured, freewheeling debates with a systematic process that drives consensus among stakeholders and assures transparency into how decisions are made.
Here's how our clients in Pharmaceuticals and Life Sciences are putting Decision Lens to work in their organizations:
Johnson & Johnson, LifeScan streamlines their strategic and business planning, resource allocation and budgeting with Decision Lens.
GlaxoSmithKline uses Decision Lens to make better decisions in clinical study approaches, critical development planning and outsource strategy.
Genentech relies on Decision Lens to facilitate decision making innovation in research and development.
Outside the private sector, the National Institutes of Health uses Decision Lens to identify specific cancer vaccine target antigens for accelerated research.